TREX1

Three prime repair exonuclease 1 (TREX1) is a protein encoded by the TREX1 gene in humans. It is a DNA exonuclease that plays a critical role in DNA repair and the maintenance of genomic stability.

Function

TREX1 is the major 3' to 5' exonuclease in mammalian cells, responsible for degrading single-stranded DNA (ssDNA) that accumulates in the cytoplasm. This activity is crucial for preventing the inappropriate activation of the immune system by self-DNA, which can lead to autoimmune diseases. TREX1 degrades DNA that results from DNA replication, DNA repair, and apoptosis.

Clinical Significance

Mutations in the TREX1 gene have been associated with several autoimmune disorders, including Aicardi-Goutières syndrome, systemic lupus erythematosus, and familial chilblain lupus. These conditions are characterized by the accumulation of DNA in the cytoplasm, which triggers an immune response through the activation of the cGAS-STING pathway.

Aicardi-Goutières Syndrome

Aicardi-Goutières syndrome (AGS) is a rare genetic disorder that mimics congenital viral infections. It is characterized by encephalopathy, calcification of the basal ganglia, and elevated levels of interferon-alpha in the cerebrospinal fluid. Mutations in TREX1 are one of the genetic causes of AGS.

Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organ systems. TREX1 mutations can lead to the accumulation of DNA, which may contribute to the development of SLE by activating the immune system.

Mechanism of Action

TREX1 functions by binding to ssDNA and cleaving it in a 3' to 5' direction. This activity is essential for the removal of DNA that could otherwise be recognized as foreign by the immune system. TREX1 is localized to the endoplasmic reticulum and is involved in the degradation of DNA that is not properly processed during DNA replication and repair.

Research Directions

Current research is focused on understanding the precise mechanisms by which TREX1 mutations lead to disease and exploring potential therapeutic strategies to modulate its activity. This includes the development of small molecule inhibitors or activators that can adjust TREX1 activity in disease contexts.

Also see

• DNA repair
• Autoimmune disease
• Exonuclease
• Aicardi-Goutières syndrome
• Systemic lupus erythematosus